Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington's Disease.

Next Previous
Trial Profile

A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs SBT 020 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms CHALLENGE-HD
  • Sponsors Stealth BioTherapeutics

    • Most Recent Events

    • 01 Feb 2018 Status changed from recruiting to completed.
    • 07 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top